Cancer Treatment Lung Injury
Cancer Treatment Lung Injury - Related Videos
11:31
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
0 Views •
Cited by 11 •
2016
We describe a method for the detection of tumor nodule development in the lungs of an adenocarcinoma mouse model using micro-computed tomography and its use for monitoring changes in nodule size over time and in response to treatment. The accuracy of the assessment was confirmed with end-point histological quantification.
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
0 Views •
2025
This protocol describes an automated, ISO15189-accredited next-generation sequencing workflow for detecting targetable genomic alterations in non-small cell lung cancer (NSCLC) formalin-fixed paraffin-embedded tissues.
06:57
Instillation and Fixation Methods Useful in Mouse Lung Cancer Research
0 Views •
Cited by 48 •
2015
The goal of this paper is to describe simple methods that will greatly aid in the setup and analysis of mouse lungs with lung cancer or other pathologies. We present 3 protocols to simply and reliably carry out lung instillations, fixation, and lung volume measurements.
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
0 Views •
2026
Here we present thoracoscopic extended sleeve lobectomy, an applicable procedure for patients with centrally located non-small-cell lung cancer that exceeds an anatomic lobe and improves the probability of complete resection while preserving respiratory capacity.
08:58
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
0 Views •
2025
This protocol describes the development of a neonatal piglet model of acute lung injury that models early pathogenic events occurring in the preterm lung, including sub-adequate surfactant quantity, hyperoxia, high-pressure ventilation, and inflammation, to facilitate understanding of molecular triggers of bronchopulmonary dysplasia and enhance therapeutic translation.
FAQs
Several pathways can contribute to progression. Therapy may initiate inflammation, immune-mediated damage to the alveoli, changes in pulmonary blood vessels, or tissue scarring. These processes can impair gas exchange and gradually reduce functional lung tissue. Recognizing the dominant pattern helps clinicians understand why respiratory symptoms may persist or advance during cancer care.
Radiation, chemotherapy, targeted drugs, and immunotherapy act through different therapeutic mechanisms, yet each can contribute to lung injury through inflammation, alveolar damage, vascular effects, or scarring. This convergence means that the treatment class alone may not explain a patient’s presentation. Clinical findings and testing remain important for identifying the relevant pattern of injury.
New respiratory findings cannot automatically be attributed to therapy because infection and advancing cancer may also be relevant explanations. Clinicians therefore compare symptoms, oxygenation, imaging findings, and pulmonary function while considering the cancer treatment history. Making this distinction supports a more appropriate response, including decisions about whether therapy should be modified.
Evaluation begins with attention to new cough, breathlessness, and oxygenation, followed by review of imaging findings and pulmonary function. These measures provide complementary information about symptoms, respiratory status, structural lung changes, and functional impairment. Clinicians interpret the results in the context of current anticancer therapy and competing possibilities such as infection or tumor progression.
Treatment adjustment becomes relevant when suspected lung injury threatens respiratory function or limits continued cancer therapy. Clinicians weigh the severity of symptoms, oxygenation, imaging changes, and pulmonary function alongside the need for effective cancer control. Early recognition can help guide timely decisions that reduce further harm while supporting preservation of lung function and ongoing care.
Research is examining risk factors and biomarkers that may identify patients more likely to develop pulmonary toxicity or reveal injury earlier. Such information could support safer, more personalized selection and monitoring of anticancer treatment. The broader goal is to recognize vulnerability before substantial lung damage occurs while maintaining therapies that provide meaningful cancer benefit.